Skip to main content

IP Update: Jul 7, 2011

Premium

Title: Transferrin/Transferrin Receptor-Mediated siRNA Delivery

Patent Number: 7,973,019

Filed: Oct. 2, 2008

Lead Inventor: Jon Chatterton, Alcon

“The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo, the patent's abstract states. “The conjugates comprise a ligand that can bind to a transferrin receptor. Therapeutic uses for the conjugates are also provided.”


Title: Compositions and Methods for Inhibiting Expression of a Gene from the Ebola Virus

Patent Number: 7,973,020

Filed: May 27, 2010

Lead Inventor: Sina Bavari, Alnylam Pharmaceuticals

“The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of a gene from the Ebola virus,” the patent's abstract states.


Title: Stable and Long-Lasting siRNA Expression Vectors and the Applications Thereof

Patent Number: 7,973,155

Filed: Feb. 14, 2006

Lead Inventor: Denis Biard, French Alternative Energies and Atomic Energy Commission

“The invention relates to a siRNA expression vector that can inhibit or eliminate the expression of a target gene in a mammalian cell,” the patent's abstract states. “The invention also relates to the applications of one such expression vector.”


Title: Stabilization and Delivery of Nucleic Acid Complexes

Application Number: 20110159098

Filed: Dec. 15, 2010

Lead Inventor: Joram Slager, SurModics

The invention, the patent application's abstract states, comprises “compositions and methods for delivering nucleic acid, including siRNA, to a target cell. ... In one embodiment, the composition includes the nucleic acid and a stabilizing protein. In another embodiment, the nucleic acid is complexed with a carrier, for example, a peptide carrier. In yet another embodiment, the nucleic acid is combined with a protein, which is cross-linked to form a proteinaceous controlled release matrix. Methods for making the compositions are also described.”


Title: Compositions and Methods for Modulating Gene Expression Using Asymmetrically Active Precursor Polynucleotides

Application Number: 20110159586

Filed: Dec. 8, 2008

Inventor: Todd Hauser, Halo-Bio

The invention, the patent application's abstract states, “is directed to novel nucleic acid molecules which include a region complementary to a target gene and one or more self-complementary regions, and the use of such nucleic acid molecules and compositions comprising the same to modulate gene expression and treat a variety of diseases and infections.”


Title: Modulation of 11 Beta-Hydroxysteroid Dehydrogenase 1 Expression for the Treatment of Ocular Diseases

Application Number: 20110160277

Filed: Oct. 25, 2006

Lead Inventor: Ana Isabel Jimenez Anton, Sylentis

“The invention relates to siNA compositions and methods for the treatment of eye conditions wherein the siNA compound [is] capable of inhibiting the expression of 11 beta-hydroxysteroid dehydrogenase,” the patent application's abstract states.


Title: Methods for Treatment and Prevention of Ototoxicity by siRNA

Application Number: 20110160279

Filed: Aug. 13, 2007

Lead Inventor: Vickram Ramkumar, Southern Illinois University

The invention relates to “methods for reducing and/or preventing ototoxicity caused by an ototoxic agent, noise, or head and/or neck radiation,” the patent application's abstract states. “It is also directed to a method for preventing or reducing generation of reactive oxygen species in the inner ear of a patient. The methods of the ... invention include administering at least one siRNA directed against TRPV1 mRNA, NOX3 mRNA or a combination thereof.”


Title: RNA Interference-Mediated Inhibition of Vascular Cell Adhesion Molecule Gene Expression Using Short Interfering Nucleic Acid

Application Number: 20110160281

Filed: Jan. 26, 2010

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

“This invention relates to compounds, compositions, and methods useful for modulating vascular cell adhesion molecule gene expression using short interfering nucleic acid molecules,” the patent application's abstract states. “This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of vascular cell adhesion molecule gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules.”


Title: Allele-Specific RNA Interference

Application Number: 20110160286

Filed: Feb. 21, 2011

Inventor: Zuoshang Xu, University of Massachusetts

The invention, the patent application's abstract states, “includes methods of specifically inhibiting the expression of a mutant allele, while preserving the expression of a co-expressed wild-type allele, using RNAi. … The invention also includes small interfering RNAs and small hairpin RNAs that selectively suppress mutant, but not wild-type, expression of copper zinc superoxide dismutase, which causes inherited amyotrophic lateral sclerosis. The ... invention further provides asymmetric siRNAs and shRNAs with enhanced efficacy and specificity and mediating RNAi.”


Title: Compositions, Device, and Methods for Treatment of Huntington's Disease Through Intracranial Delivery of siRNAs

Application Number: 20110160707

Filed: Feb. 16, 2011

Inventor: William Kaemmerer, University of Minnesota

The invention comprises “devices, small interfering RNAs, and methods for treating a neurodegenerative disorder comprising the steps of surgically implanting a catheter so that a discharge portion of the catheter lies adjacent to a predetermined infusion site in a brain, and discharging through the discharge portion of the catheter a predetermined dosage of at least one substance capable of inhibiting production of at least one neurodegenerative protein,” the patent application's abstract states. The invention also provides “small interfering RNA vectors, systems, and methods for treating Huntington's disease in vivo without impairment of cell endoplasmic reticulum, spontaneous motor activity, or locomotor activity of a patient.”


Title: Identification of miRNA Profiles That Are Diagnostic of Hypertrophic Cardiomyopathy

Application Number: 20110160285

Filed: March 12, 2009

Lead Inventor: Emily Anderson, Dharmacon (Thermo Fisher Scientific)

The invention, the patent application's abstract states, comprises “a collection of miRNAs and genes whose expression is altered in hypertrophic cardiomyopathy. Accordingly, these miRNAs and genes, singly or in combination, are useful as molecular markers for diagnosis or prognosis of hypertrophic cardiomyopathy. The miRNAs and genes disclosed can also be therapeutic targets for cardiac hypertrophy.”


Title: Use of Extracellular RNA to Measure Disease

Application Number: 20110160290

Filed: May 21, 2009

Inventor: Muneesh Tewari, Fred Hutchinson Cancer Research Center

The invention, the patent application's abstract states, comprises “stable, extracellular microRNAs and methods for isolating and identifying such microRNAs from a body fluid. ... The extracellular microRNAs isolated from a bodily fluid of a subject can be used to measure disease and provide sensitive, efficient, and non-invasive methods for the detection of disease, including cancer. The extracellular microRNAs can be used to develop new therapeutics for the treatment of disease, including cancer. The examples illustrate diagnosis of prostate and ovarian cancer and differential expression of miR-100, miR-135b, miR-141, miR-148a, miR-200a, miR-200c, miR-210, miR-222, miR-375, miR-425-Sp, and miR-429.”

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.